Study of Interleukin 6 as marker of inflammation and a predictor of in-hospital complications in patients with acute coronary syndrome
The Medical Journal of Basrah University,
2020, Volume 38, Issue 2, Pages 115-119
Although abnormal fatty deposits of infected arterial plaque play a major role in the formation of atherosclerotic plaque, activation of inflammatory cells plays a major role in the instability of the plaque and the cause of acute coronary syndrome. The aim of this study was to measure the level of interleukin-6 and to study its association with complications that occur in hospital in patients with acute coronary syndrome.
One hundred and twenty-five patients with acute coronary syndrome and 120 healthy individuals as a control group were included in this study. According to ECG and serum troponin changes, the patient group was classified into three ST-elevated myocardial infarction, ST non-elevated myocardial infarction and unstable angina. Sandwich ELISA was used by commercial groups (LEGAND MAX TM) for the IL-6 assay.
This study shows significantly significant differences in the level of IL-6 in patients with acute coronary syndrome (73.37 pg / dL) compared to the control group (9.47 pg / dL) (P value 0.001)
There were no significant differences at the level of IL-6 in patients with acute coronary syndrome and conventional risk factors (P. value <0.05).
There were significant differences in the level of IL-6 in all forms of ACS. (P. value 0.001). And those patients who had complications in hospital had a higher IL-6 level (92.89 Pg / dl) than those without complications (68.83 Pg / dl) P. value (0.012).
This study indicated that IL-6 was significantly elevated in ACS patients
- Article View: 236
- PDF Download: 213